The practice of authorised generics has recently been the subject of considerable attention by the pharmaceutical industry, regulators, and members of Congress alike. An authorised generic (sometimes termed a branded, flanking, or pseudo generic) is a pharmaceutical that is marketed by or on behalf of a brand name drug company, but is sold under a generic name. Although the availability of an additional competitor in the generic drug market would appear to be favourable to consumers, authorised generics have nonetheless proven controversial. Some observers believe that authorised generics potentially discourage independent generic firms both from challenging drug patents and from selling their own products. This book presents an analysis of the innovation and public health issues relating to authorised generic drugs. The book begins with a review of the procedures through which independent generic drug companies receive government permission to market their products and resolve patent disputes with brand-name firms. It also provides detailed background information pertaining to the concept of authorised generics and assesses their potential impact upon patent challenges and consumer welfare, as well as a summary of congressional issues and possible alternatives.
Preface; Authorised Generic Pharmaceuticals:: Effects on Innovation; Paying Off Generics to Prevent Competition with Brand Name Drugs:: Should It Be Prohibited? Hearing before the Committee on the Judiciary, United States Senate, 17 January 2007; Safe and Affordable Biotech Drugs:: The Need for A Generic Pathway, Hearing before the Committee on Oversight and Government Reform, House of Representatives, 26 March 2007; Index.
Comments (0)
Your review appreciation cannot be sent
Report comment
Are you sure that you want to report this comment?
Report sent
Your report has been submitted and will be considered by a moderator.